Inhibition or Deletion of Soluble Epoxide Hydrolase Prevents Hyperglycemia, Promotes Insulin Secretion, and Reduces Islet Apoptosis
- 3 May 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 334 (2), 430-438
- https://doi.org/10.1124/jpet.110.167544
Abstract
Soluble epoxide hydrolase (sEH) is an enzyme involved in the metabolism of endogenous inflammatory and antiapoptotic mediators. However, the roles of sEH in diabetes and the pancreas are unknown. Our aims were to determine whether sEH is involved in the regulation of hyperglycemia in diabetic mice and to investigate the reasons for the regulation of insulin secretion by sEH deletion or inhibition in islets. We used two separate approaches, targeted disruption of Ephx2 gene [sEH knockout (KO)] and a selective inhibitor of sEH [trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB)], to assess the role of sEH in glucose and insulin homeostasis in streptozotocin (STZ) mice. We also examined the effects of sEH KO or t-AUCB on glucose-stimulated insulin secretion (GSIS) and intracellular calcium levels in islets. Hyperglycemia in STZ mice was prevented by both sEH KO and t-AUCB. In addition, STZ mice with sEH KO had improved glucose tolerance. More important, when insulin levels were assessed by hyperglycemic clamp study, sEH KO was found to promote insulin secretion. In addition, sEH KO and t-AUCB treatment augmented islet GSIS. Islets with sEH KO had a greater intracellular calcium influx when challenged with high glucose or KCl in the presence of diazoxide. Moreover, sEH KO reduced islet cell apoptosis in STZ mice. These results show not only that sEH KO and its inhibition prevent hyperglycemia in diabetes, but also that sEH KO enhances islet GSIS through the amplifying pathway and decreases islet cell apoptosis in diabetes.Keywords
This publication has 38 references indexed in Scilit:
- Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammationJournal of Molecular and Cellular Cardiology, 2010
- Heat Shock Protein 27 Overexpression Mitigates Cytokine-Induced Islet Apoptosis and Streptozotocin-Induced DiabetesEndocrinology, 2009
- Soluble Epoxide Inhibition Is Protective Against Cerebral Ischemia via Vascular and Neural ProtectionThe American Journal of Pathology, 2009
- The Insulin Receptor Talks to Glucagon?Cell Metabolism, 2009
- Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammationBritish Journal of Pharmacology, 2009
- MKK3 signalling plays an essential role in leukocyte-mediated pancreatic injury in the multiple low-dose streptozotocin modelLaboratory Investigation, 2008
- Mechanisms linking obesity to insulin resistance and type 2 diabetesNature, 2006
- Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile FunctionCirculation Research, 2006
- Uncoupling Protein-2 Negatively Regulates Insulin Secretion and Is a Major Link between Obesity, β Cell Dysfunction, and Type 2 DiabetesCell, 2001
- Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic isletsBiochemical and Biophysical Research Communications, 1983